Pharmafile Logo
Pharmafocus logo
Advanced Search

CAR T

Showing 15 posts of 31 posts found.

shutterstock_3

EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma

October 20, 2020
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma

Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …

News
spotlighton-aprile-cw_covid-19-and-cancer-1-img

Oncology research in the age of COVID-19

September 14, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, pharma

Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive …

Feature
covidgenome

FDA approves Phase 1 trial for HIV gene therapy

August 24, 2020
Sales and Marketing CAR T, CAR T cancer therapies, CAR-T

The FDA has approved a request from American Gene Technologies to begin a clinical study into its HIV gene therapy. …

News
fda

Poseida suspends CAR T therapy trial in prostate cancer due to patient death

August 18, 2020
Manufacturing and Production, Research and Development CAR T, CAR-T, Poseida, patient death, pharma

Poseida’s Phase 1 trial that used an investigational CAR T therapy for treating prostate cancer has been suspended due to …

News
1

CAR T cell therapy is revolutionising cancer treatment, but at what cost?

August 3, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature

CAR T cell therapy is one of the latest innovations in gene therapy. The process is primarily used to treat …

Feature
fdaoutsideweb

Kite secures FDA approval for second CAR T therapy Tecartus in relapsed or refractory mantle cell lymphoma

July 27, 2020
Sales and Marketing CAR T, CAR-T, FDA, Gilead, kite pharma

Kite Pharma has chalked up another regulatory success for its parent company Gilead with the news that the FDA has …

News
janssen_latest_logo_on_sign_closer

100% of multiple myeloma patients respond to Janssen’s investigational CAR T therapy, data shows

May 14, 2020
Research and Development CAR T, CAR-T, Janssen, multiple myeloma, pharma

Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell …

News
gilead-sciences

Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

October 8, 2019
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, CAR T, CAR-T, Eli Lilly, Lexicon, Medicare, Novartis, Pfizer, Sanofi, pharma

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …

News
novartis_window

Novartis’ Kymriah to be covered by Japan’s national insurance system

May 16, 2019
Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma

Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …

News
novartis_window

Canada Health approves Novartis’ CAR-T therapy Kymriah

January 18, 2019
Medical Communications CAR T, CAR-T, Canada, Cancer, Kymriah, Novartis, oncology

Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and …

News

Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million

December 20, 2018
Business Services, Medical Communications, Sales and Marketing CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncology

German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a …

News
acute_lymphoblastic_leukaemia_smear

20 year old man died after leukaemia cell was accidently mixed into CAR T therapy

October 2, 2018
Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology

A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …

News
novartis_window

Novartis strike $40m deal with Chinese firm Cellular Biomedicine

September 28, 2018
Medical Communications CAR T, CAR-T, China, Kymriah, Novartis, cellular biomedicine, prc

Swiss multinational Novartis have paired up with Chinese drugmaker Cellular Biomedicine (CBMG) in order to manufacture CAR-T therapy Kymriah in …

News
white-blood-cell-543471_1920

NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process

September 25, 2018
Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing

Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024